Eksempler på bruk av Should not be used in patients på Engelsk og deres oversettelse til Norsk
{-}
-
Colloquial
-
Ecclesiastic
-
Ecclesiastic
-
Computer
Pioglitazone should not be used in patients with hepatic impairment(see section 4.3 and 4.4).
Pioglitazone should not be used in patients with hepatic impairm nt(see section 4.3 and 4.4).
Pioglitazone should not be used in patients with hepatic impairment(see section 4.3 and 4.4).
EVISTA should not be used in patients with signs or symptoms of endometrial cancer as safety in this patient group has not been adequately studied.
Raloxifene should not be used in patients with signs or symptoms of endometrial cancer as safety in this patient group has not been adequately studied.
SonoVue should not be used in patients under 18 years of age as it has not been studied in these groups.
Eucreas should not be used in patients with hepatic impairment,
Empagliflozin should not be used in patients with end stage renal disease(ESRD)
Cardiac arrhythmia(Model 106 only)- The AutoStim Mode feature should not be used in patients with clinically meaningful arrhythmias or who are using treatments that interfere with normal intrinsic heart rate responses(e.g., pacemaker dependency, implantable defribrillator, beta adrenergic blocker medications).
Cardiac arrhythmia(Model 106 only)- The AutoStim Mode feature should not be used in patients with clinically meaningful arrhythmias
Abacavir should not be used in patients known to carry the HLA-B*5701 allele.
Therefore, it should not be used in patients with baseline haemoglobin> 13 g/dl.
Consequently, Enbrel should not be used in patients for the treatment of alcoholic hepatitis.
Therefore, RILUTEK should not be used in patients with any other form of motor neurone disease.
Due to its pioglitazone component, Incresync should not be used in patients with hepatic impairment(see section 4.2).
Therefore, epoetin alfa should not be used in patients with baseline haemoglobin> 13 g/dl> 8.1 mmol/l.
As this medicinal product contains saxagliptin, it should not be used in patients who have had any serious hypersensitivity reaction to a dipeptidyl peptidase 4(DPP4) inhibitor.
The efficacy and safety of dabrafenib have not been established in patients with wild-type BRAF melanoma or wild-type BRAF NSCLC therefore dabrafenib should not be used in patients with wild- type BRAF melanoma
Due to the risk of serious rhythm disturbances, Gilenya should not be used in patients with second degree Mobitz type II
Ralista should not be used in pediatric patients.